Department of Immune Modulation, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Department of Internal Medicine 2, University Hospital Erlangen, FAU, Erlangen, Germany.
Front Immunol. 2022 Sep 30;13:1012647. doi: 10.3389/fimmu.2022.1012647. eCollection 2022.
To facilitate the recovery process of chronic and hard-to-heal wounds novel pro-resolving treatment options are urgently needed. We investigated the pro-regenerative properties of soluble CD83 (sCD83) on cutaneous wound healing, where sCD83 accelerated wound healing not only after systemic but also after topical application, which is of high therapeutic interest. Cytokine profile analyses revealed an initial upregulation of inflammatory mediators such as TNFα and IL-1β, followed by a switch towards pro-resolving factors, including YM-1 and IL-10, both expressed by tissue repair macrophages. These cells are known to mediate resolution of inflammation and stimulate wound healing processes by secretion of growth factors such as epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF), which promote vascularization as well as fibroblast and keratinocyte differentiation. In conclusion, we have found strong wound healing capacities of sCD83 beyond the previously described role in transplantation and autoimmunity. This makes sCD83 a promising candidate for the treatment of chronic- and hard-to-heal wounds.
为了促进慢性和难以愈合的伤口的恢复过程,迫切需要新的促愈治疗选择。我们研究了可溶性 CD83(sCD83)对皮肤伤口愈合的促再生特性,发现 sCD83 不仅在全身应用后,而且在局部应用后也能加速伤口愈合,这具有很高的治疗意义。细胞因子谱分析显示,最初炎症介质如 TNFα 和 IL-1β 上调,随后转向促愈合因子,包括 YM-1 和 IL-10,它们均由组织修复巨噬细胞表达。这些细胞通过分泌表皮生长因子 (EGF) 和血管内皮生长因子 (VEGF) 等生长因子来介导炎症的消退和刺激伤口愈合过程,从而促进血管生成以及成纤维细胞和角质细胞的分化。总之,我们发现 sCD83 具有很强的伤口愈合能力,超出了其在移植和自身免疫中已描述的作用。这使得 sCD83 成为治疗慢性和难以愈合的伤口的有前途的候选药物。